Pfizer’s Boshoff assumes oncology leadership role in shuffle
Plus: SVB bolsters its life science and healthcare sector with two new appointments, and updates from Concerto and Annexon
Pfizer Inc. (NYSE:PFE) said oncology executive Chris Boshoff will become the “single point of accountability for the entire oncology pipeline” upon his promotion Thursday to chief oncology R&D officer and EVP, reporting to Chairman and CEO Albert Bourla. The company also said R&D leader Mikael Dolsten will take the new title of CSO and president of Pfizer’s R&D, with responsibility for all non-oncology discovery, early and late-stage development. EVP and Chief Development Officer William Pao, who joined Pfizer last year from Roche (SIX:ROG; OTCQX:RHHBY), will leave the pharma.
The Silicon Valley Bank division of First Citizens Bank named Jackie Spencer as head of relationship management for life science and healthcare banking, and Megan Scheffel as head of credit solutions for the life science and healthcare practice. Spencer and Scheffel are both veterans of SVB, which was acquired by First Citizens in March. ...